Hints and tips:
...Eli Lilly will join Pfizer in reporting before the opening bell....
...India, which passed 5m cases, will buy 100m doses of Russia’s Sputnik-V vaccine candidate. Eli Lilly’s antibody treatment reduced hospitalisations....
...It has also signed deals with Vir Biotechnology to produce Covid-19 antibody products and with Eli Lilly and AstraZeneca to produce Covid-19 treatments. Song Jung-a 74....
...In sifting through the S&P 500, it has chosen to only include companies with 0-45 per cent tax rates, so as to eliminate bizarre outliers such as pharmaceutical company Eli Lilly, who reported a tax rate...
...The government has vowed to tackle the price of cancer medicines, threatening revenues for multinationals such as Eli Lilly, Roche and Novartis....
...With these efforts, Eli Lilly hopes to achieve annualised savings of about $500m from 2018, which will be “equally split” to improve cost structure and reinvest in the business....
...Pfizer dropped 1.2 per cent, Merck shed 2 per cent while Eli Lilly and Bristol-Myers Squibb both lost 1 per cent....
...Rival Eli Lilly announced job cuts and a focus on new medicines while AstraZeneca was boosted by good news on its cancer pipeline....
...Caterpillar, United Technologies, Biogen and Eli Lilly all reported strong earnings before the bell....
...In earnings, Boeing and Eli Lilly report before the bell, while Microsoft, Facebook, AT&T and Qualcomm come after the market closes....
...) Eli Lilly mulls spin-off or sale of animal health business (FastFT) Cargill ramps up animal nutrition business with Diamond V deal (FastFT) Asian buyers tap into ‘pampered pooch’ market (FT) ICE to...
...Eli Lilly shares will rally by almost a fifth over the next year given the pharmaceutical group’s slim reliance on drug price increases and a strong roster of treatments in its pipeline, Goldman Sachs said...
...Elsewhere, Eli Lilly shares were in demand after the drugmaker predicted its sales and profits would be higher than expected next year....
...The stock rose by the most in a month — hitting a session high of $306.98 before paring its gains to $301.28 — after phase 3 trial data from rival Eli Lilly’s solanezumab treatment suggests that Biogen’s...
...Drugmakers Pfizer, Merck and AbbVie rose more than 6 per cent, while Eli Lilly and Amgen climbed more than 5 per cent....
...Pharmaceutical stocks received a shot in the arm after analysts at Barclays upgraded Eli Lilly and Merck citing optimism over their pipelines of drugs....
...Eli Lilly shares shed 8 per cent at $79.45 by the close of trading. On the other side of the spectrum, companies that were recently approved for new cholesterol drugs climbed on the day....
...Eli Lilly fell 3.6 per cent to $71.24 after the US pharmaceuticals group said it was changing the scientific goal of a closely watched Phase 3 clinical trial of solanezumab, an Alzheimer’s drug....
...Elsewhere, Eli Lilly jumped after the US drugmaker won a patent case that bars rival Actavis from selling a generic form of its blockbuster Alimta cancer drug in the UK before the patent expires in 2021....
...Shares in Eli Lilly advanced as much as 5 per cent, but ended the day only 0.8 per cent higher at $71.61....
...Shares in US drugmaker Eli Lilly dipped slightly to $69.23 after it forecast 2015 adjusted earnings in the range of $3.10-$3.20 a share, below expectations of $3.36....
...Milder patients who had received Eli Lilly’s Solanezumab had shown a slowed rate of cognitive decline....
...Analysts at Credit Suisse have estimated the market for ramucirumab could top $800m per year by 2020, or 4 per cent of Eli Lilly’s overall sales....
...An FDA warning was eventually issued but Takeda and Eli Lilly, which marketed the drug in the US, say the cancer link remains unproved....
...Merck is not alone, as drugmaker Eli Lilly – up only 3.2 per cent in 2013 – has also struggled to compete with lower-priced generic versions of its most lucrative products....
International Edition